Overview of Iverhart Plus

Iverhart Plus is a prescription-only veterinary medicine used for the comprehensive internal parasite control of dogs. Manufactured by Virbac, it is a combination product that delivers two distinct active ingredients in a single flavored chewable tablet for once-monthly oral administration.

Quick Facts: Iverhart Plus Identity

Property	Description
Active Ingredients	Ivermectin, Pyrantel Pamoate
Form	Flavored Chewable Tablet
Pharmacological Class	Antiparasitic Anthelmintic Agents
Common Use	Heartworm Prevention, Roundworm and Hookworm Control
Target Patient Group	Dogs, including puppies 6 weeks of age and older

Definition and Pharmacological Classification

Iverhart Plus is officially classified as a combination antiparasitic anthelmintic agent. This classification means the medication is designed to fight various parasitic worms in the canine population. The product is distinguished by its palatable, pork-liver flavored chewable tablet, which is formulated to ensure consistent dosing.

This specific combination is clinically recognized for its wide margin of safety and is approved for use in puppies as young as six weeks old, providing a crucial option for early-life parasite control.

Composition and Dual-Active Formula

The medication's efficacy is based on two key active ingredients: Ivermectin and Pyrantel, included as the Pyrantel Pamoate salt. Ivermectin is chemically a semi-synthetic macrocyclic lactone derivative, while Pyrantel is a distinct, synthetic pyrimidine derivative.

This intentional pairing of chemically diverse compounds ensures two separate high-level mechanisms of effect against different parasite types and life stages. This dual approach functions to interrupt the heartworm lifecycle and control common intestinal nematodes.

Primary Prophylactic Purpose for Canine Health

The general purpose of Iverhart Plus is to provide continuous prophylaxis (prevention) against heartworm disease and therapeutic control of specific intestinal parasitic infestations in dogs. The primary action is designed to eliminate the tissue larval stage of Dirofilaria immitis that the dog may have acquired over the prior month.

Beyond heartworm prevention, the formulation is simultaneously indicated for treating and controlling common gastrointestinal parasitic worms, specifically roundworms and hookworms. This dual benefit ensures that the routine administration contributes significantly to a comprehensive regimen for maintaining overall canine internal parasite health.

Regulatory References

What side effects are possible with Iverhart Plus?

Possible Side Effects and Safety Information

This information details the officially documented adverse reactions and safety constraints for Iverhart Plus, strictly based on government regulatory labeling.

Adverse Reaction Scope

The most commonly reported adverse reactions involve the gastrointestinal and nervous systems. In clinical trials, vomiting or diarrhea within 24 hours of dosing was rarely observed (reported in 1.1% of administered doses).

System-Organ Class Involved	Documented Adverse Reactions
Gastrointestinal	Vomiting, diarrhea, anorexia (decreased appetite), hypersalivation
Nervous System	Depression/lethargy, ataxia (staggering), convulsions, tremors, mydriasis (dilated pupils)

Serious Adverse Reactions and Sensitive Populations

Serious Adverse Reactions: Reactions such as convulsions, severe staggering/ataxia, and depression have been reported following the use of ivermectin. Severe signs, including coma and death, were observed in sensitive breeds when given elevated doses (more than 16 times the target dose).

Population-Specific Safety:

Breeds: Certain dogs of the Collie breed are more sensitive to the effects of ivermectin at high doses.
Reproductive Status: The safe use of this drug has not been evaluated in pregnant or lactating bitches.
Age and Health: Recommended for use in dogs 6 weeks of age and older. Use with caution in sick, debilitated, or underweight animals, and dogs weighing less than 10 lbs.

Safety Restrictions and Limitations

Mandatory Screening: All dogs must be tested for existing heartworm infection before starting treatment. If infected, dogs should be treated to remove adult heartworms and microfilariae before initiating a preventive program. A mild hypersensitivity-type reaction (transient diarrhea) has been observed in heartworm-positive dogs due to dead microfilariae.

Dose-Related Effects: In animal safety studies, elevated, long-term doses (3 and 5 times the maximum recommended dose for 6 months) were associated with a decrease in testicular maturation in Beagle puppies.

Regulatory Safety Summary: The official safety structure establishes that while gastrointestinal and neurological effects are the primary reported adverse reactions, the most serious risks are tied to dose-related toxicity in sensitive breeds and the required pre-treatment testing for heartworm infection.

Overdose and Emergency Response

The official overdose profile for Iverhart Plus is primarily defined by the severe clinical manifestations and progression documented at elevated dose levels of the Ivermectin component, as stated in regulatory sources.

Documented Overdose Manifestations

Manifestations reported in regulatory documents include a progression of neurological signs such as mydriasis (pupil dilation), tremors, ataxia (loss of coordination), and depression. Gastrointestinal signs may include vomiting, diarrhea, and hypersalivation. Severe, life-threatening outcomes are documented to progress to paresis, recumbency, stupor, coma, and ultimately death.

Overdose Context & Sensitivity	Official Regulatory Statement
Dose-Related Factor	Clinical signs are documented at elevated dose levels (e.g., more than 16 times the target dose) of the Ivermectin component.
Population Notes	Dogs of the Collie breed and related dogs are noted in regulatory documents as being more sensitive to the effects of toxicity at elevated doses.

Emergency Action & Management	Official Regulatory Statement
Required Action	In case of human ingestion, the mandate is to contact a physician immediately. Physicians may seek advice from a Poison Control Center.
Management Basis	No specific antidote is explicitly known or listed in the official labeling; management focuses on symptomatic and supportive treatment.

The regulatory documentation defines the overdose profile by detailing the severe, dose-dependent neurotoxicity and its progression to potentially life-threatening outcomes. The profile explicitly provides clear, non-negotiable instructions for immediate physician contact in cases of human ingestion, establishing the required emergency help-seeking standard.

Therapeutic Uses of Iverhart Plus

What Iverhart Plus treats: main uses and benefits

Iverhart Plus is primarily utilized to provide protection against the risk of heartworm disease in dogs, a serious, potentially life-threatening condition caused by the parasite Dirofilaria immitis. Consistent monthly application, as directed by a veterinary professional, is a critical element in preventing the development of the larval heartworm stage. This preventative measure supports the maintenance of the dog's cardiac and pulmonary function.

Furthermore, the medication assists in the treatment and control of several common intestinal parasites. The formula is indicated for the removal of roundworms (Toxocara canis and T. leonina) and hookworms (Ancylostoma caninum and Uncinaria stenocephala). Managing these parasites is essential for maintaining your dog's gastrointestinal health and may help address related symptoms such as discomfort or loss of condition.

Quick Fact: Relief for Intestinal Parasitic Burden

Eligibility and Restrictions for Use

The official eligibility profile for Iverhart Plus is strictly defined by regulatory criteria, focusing on age, heartworm status, and known sensitivities.

Populations Permitted for Use

The medication is formally approved for use in dogs and puppies six (6) weeks of age and older. The official labeling confirms the drug's safety is established at the recommended dose for special populations, including pregnant or breeding female dogs and stud dogs.

Populations with Prohibitions or Restrictions

Regulatory documents establish specific criteria for non-eligibility and conditional use:

Absolute Prohibition: The drug is not to be used in dogs with a known hypersensitivity to ivermectin, pyrantel, or any component of the chewable tablet.
Conditional Use: Dogs must be tested and confirmed heartworm-negative before initiating the preventative program. Dogs with an existing adult heartworm infection must be treated to clear the microfilariae, as the drug is not effective against the adult parasite stage.
Breed Consideration: While certain Collie-related breeds are known to be sensitive to ivermectin at elevated dose levels, the product's safety has been confirmed in these breeds when administered at the standard preventative dose.

What should I know about interactions with other medicines?

Iverhart Plus Interactions with other medicines and products

The official interaction profile of Iverhart Plus is determined by the properties of its dual active ingredients, as documented in government regulatory labeling.

Transporter-Mediated Exposure

The Ivermectin component is a substrate for the P-glycoprotein (P-gp) efflux transporter, a mechanism documented to regulate its distribution. Co-administration with medicines classified as P-gp Inhibitors can alter the drug exposure profile, leading to increased concentrations in the Central Nervous System. Examples of substance classes involved in this interaction include Azole Antifungals and certain Calcium Channel Blockers.

Pharmacodynamic Restrictions

The Pyrantel Pamoate component may cause pharmacodynamic reinforcement when administered alongside other agents that possess similar neuromuscular activity. Official labeling suggests caution or restriction when combining this product with other cholinergic anthelmintics, such as Levamisole and Piperazine, or with Organophosphates due to the risk of additive effects.

Population-Specific and Co-administration Notes

A population-specific note highlights that dogs with the MDR1 gene mutation are genetically predisposed to higher susceptibility to adverse outcomes when the function of P-gp is inhibited. The regulatory document also notes that commonly used products, including antibiotics, vaccines, and steroid preparations, have been administered concurrently in clinical trials without specific interaction-related restrictions at the heartworm prevention dose. The product is permitted to be administered with or without food.

Mechanism of Action

Iverhart Plus acts through two fundamentally distinct and complementary pharmacological mechanisms on its target parasites, which utilizes the specific vulnerabilities of their nervous systems to result in parasite termination.

Ivermectin: Selective Parasite Neuromuscular Inhibition

Ivermectin operates by selectively targeting Glutamate-gated Chloride Channels (GluCl), a pathway unique to invertebrate nerve and muscle cells. Its action as an activator and modulator of these channels causes a massive and sustained influx of chloride ions ( Cl^-). This molecular event leads to profound hyperpolarization and electrical silencing of the parasite's nerve and muscle cells, resulting in a flaccid paralysis that halts motility and feeding.

Pyrantel Pamoate: Cholinergic Neuromuscular Depolarization

Pyrantel Pamoate employs a contrasting mechanism by acting as a Cholinergic Agonist on Nicotinic Acetylcholine Receptors (nAChRs) in the muscle system of intestinal worms. This persistent stimulation drives the muscle cells into continuous depolarization and uncontrollable, sustained contraction. The resulting spastic (tetanic) paralysis prevents the worms from maintaining attachment to the intestinal wall, which results in their passive displacement from the intestinal wall.

This intentional combination of Ivermectin's systemic, inhibitory mechanism and Pyrantel Pamoate's localized, excitatory mechanism provides a wide-ranging, additive influence across distinct life stages and anatomical locations within the host.

Dosage and Administration Information

How to Use Iverhart Plus: Administration Guidelines

Iverhart Plus is a prescription-only veterinary medicine that is administered according to a strict, high-level regimen focused on the dog’s weight and a precise monthly schedule. The use of the product involves specific parameters for the route, frequency, and dose ranges.

Administration Scope

Instruction Category	Guideline
Route of administration:	Oral administration only, via a flavored chewable tablet
Dosing schedule:	Weight-banded dosing to ensure a minimum of 6.0 mu g/kg of Ivermectin and 5.0 mg/kg of Pyrantel Pamoate is delivered based on body weight.
Frequency and timing:	Once-monthly (every 30 days), administered on or about the same day each month.
Timing in relation to meals:	The chewable tablet can be offered directly or mixed with a small amount of food to facilitate consumption.
Age-group rules:	Approved for use in dogs six weeks of age and older.

Resulting Procedural Structure

The protocol requires the veterinarian to select one of the product's three standardized strengths based on the dog's weight. The owner is instructed to administer the single, intact chewable tablet once per month throughout the heartworm season, or year-round in endemic areas. The entire dose must be consumed; observation of the dog immediately after administration ensures the full amount is taken, with redosing required if the tablet is lost or rejected. If a dose is missed or delayed, immediate administration is required, and the monthly schedule must be resumed to maintain consistent protection.

Recent Clinical Evidence

Research evidence / Overview of studies for Iverhart Plus

Heartworm Disease Prevention

Research has explored Iverhart Plus in the context of research exploring the approach to heartworm parasite exposure, a condition characterized by functional limitations in dogs. These are typically controlled field studies and trials evaluating short-term or episodic symptom patterns, often conducted during periods of increased mosquito activity, as mosquitoes are the carriers of the disease.

Studies monitored the animals following potential exposure to the parasite and subsequent administration of the product. The data show patterns related to changes observed in the development of the heartworm parasite larval stage for a defined period (one month) following potential infection in the dogs studied. Research highlights changes measured during the study period, indicating that the combination of active ingredients (ivermectin and pyrantel) was studied in research evaluating the parasite's life cycle.

While findings describe patterns observed in the studies, the evidence is limited in certain areas. For instance, the research does not determine whether an individual animal will respond similarly, as the findings describe group patterns, not personal outcomes. Long-term effects and the possibility of resistance development are not fully established across all regions, and comparative evidence against certain newer preventive strategies is lacking.

Treatment and Control of Roundworms and Hookworms

Studies examined Iverhart Plus in research exploring outcomes related to the study of certain intestinal parasites, specifically roundworms and hookworms. These outcomes related to physical discomfort or systemic imbalance in the animal subjects were monitored in observational settings evaluating daily-life functioning. The active ingredient pyrantel pamoate was studied in research exploring outcomes related to these parasites, which can cause conditions involving periods of heightened symptoms or functional issues in the digestive system.

The research describes that the product contributes to understanding symptom patterns by exploring outcomes related to these intestinal parasites. Data show patterns related to measured changes in parasite load in the animals observed. Studies monitored for patient-reported outcomes describing perceived discomfort or changes in stool quality, reporting how symptoms evolved in the observed populations during the study period.

For certain groups, data remain insufficient. Use of the product was observed in some studies that included pregnant or breeding animals and puppies aged six weeks or more, but results apply only to the populations studied. Comparative evidence against other broad-spectrum dewormers is lacking, and subgroup findings regarding specific breeds or compromised animals are uncertain. Follow-up durations were limited in some early trials exploring these short-term changes. Research is ongoing to better contextualize how this approach fits into the broader evidence landscape of parasite control.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Iverhart Plus (FAQ)

Q: How quickly does Iverhart Plus start working after taking it?

Regulatory documents indicate the product is designed to eliminate the heartworm parasite's tissue larval stage acquired in the preceding 30 days. The required once-monthly schedule aims to ensure effectiveness following potential infection.

Q: What is the typical length of time Iverhart Plus stays in the body?

The drug is part of a once-monthly regimen designed to cover the risk of infection acquired over a 30-day period. The necessity for this schedule is based on regulatory guidance for maintaining consistent prophylactic coverage against heartworm.

Q: Why do people choose Iverhart Plus over other similar products?

The drug is officially described as a combination antiparasitic agent that provides two uses in one: heartworm prevention and control of specific roundworms and hookworms. This dual benefit is delivered in a single, flavored chewable tablet for once-monthly administration.

Q: Is it possible to have an allergic reaction to Iverhart Plus?

Official labeling advises that the drug is prohibited for use if there is a known hypersensitivity (allergic reaction) to any component of the tablet. A mild hypersensitivity-type reaction has also been observed in heartworm-positive patients when initiating the medication.

Q: What are the most commonly reported non-serious side effects of Iverhart Plus?

The most commonly reported non-serious effects involve the digestive system. In clinical trials, official reports indicate that vomiting or diarrhea within 24 hours of dosing was observed in a very small percentage of cases (about 1.1% of doses). Other reported reactions include decreased appetite (anorexia), increased salivation, and depression/lethargy.

Q: Are there any specific warning signs mentioned in the official documents for Iverhart Plus?

Regulatory safety documents list adverse reactions that involve the nervous system, which may signal a need for attention. These include reports of depression/lethargy, staggering (ataxia), and uncontrolled muscle movements (convulsions) that have been documented following the use of ivermectin products.

Q: Can Iverhart Plus be used with other regular medications?

Official documents note that many commonly used products were administered concurrently in clinical trials without specific interaction-related restrictions at the heartworm prevention dose. These include classes of medicines such as antibiotics, vaccines, and steroid preparations.

Q: Are there any known differences between Iverhart Plus and generic versions of the ingredients?

Iverhart Plus is a branded product approved by a regulatory agency through an Abbreviated New Animal Drug Application (ANADA). This classification indicates that the product has been demonstrated to be bioequivalent to a previously approved brand-name product and contains the same active components.

Q: Is Iverhart Plus considered a widely studied medication?

Yes, regulatory approval is supported by documentation referencing multiple studies, including controlled field studies and bioequivalency studies. These investigations explore its efficacy in heartworm prevention and confirm its safety profile at the recommended preventive dose.

Q: Is it common for people to feel nauseous after using Iverhart Plus?

Iverhart Plus is a prescription animal drug specifically approved for oral use in dogs only. The product's safety information, including all reported adverse reactions like vomiting or nausea, refers exclusively to effects observed in the intended species, which is dogs.

Q: Can Iverhart Plus be used by individuals with certain kidney conditions?

Iverhart Plus is a prescription animal drug intended and approved for use only in dogs. Its official safety and usage information does not contain details about its use or effects in humans or human medical conditions.

Q: What is the risk classification of Iverhart Plus in official drug guides?

Iverhart Plus is officially classified as a Prescription Animal Drug by regulatory bodies in the United States. This means its distribution is restricted and it can only be obtained with an order from a licensed veterinarian. The medication is not assigned a DEA Schedule.

Q: Is Iverhart Plus a prescription-only drug in most places?

In the United States, the regulatory label contains a Caution Statement confirming its status as a prescription-only product. This restriction limits its dispensing to be 'by or on the order of a licensed veterinarian.'

Q: What is meant by the 'mechanism of action' of Iverhart Plus?

The drug's action is defined by its two ingredients. Ivermectin primarily works by affecting the parasite's nerve cells, leading to paralysis. The second ingredient, Pyrantel Pamoate, causes a sustained muscle contraction, or spastic paralysis, specifically in intestinal worms.

Q: Is it true that Iverhart Plus is used differently depending on where you live?

Yes, the frequency of use can vary by location. Official administration instructions advise that the chewable should be given monthly during the entire period when mosquitoes (which carry heartworm larvae) are active. This period is longer or year-round in certain geographic regions.

Q: What if someone accidentally takes more Iverhart Plus than recommended?

The official product label provides a clear warning regarding accidental consumption by humans. In the case of ingestion by humans, clients are specifically advised to contact a physician immediately.

Q: Does Iverhart Plus carry a Black Box Warning in the official FDA documents?

The official Food and Drug Administration (FDA) label for Iverhart Plus does not contain a Black Box Warning. This warning is the most serious safety alert that the FDA can place on pharmaceutical products.

Q: What are the limitations of the existing research on Iverhart Plus?

Official documents highlight several limitations. For example, the drug's safety has not been evaluated in pregnant or lactating bitches. Regulatory documents state that the drug is to be used with caution in sick, debilitated, or underweight animals.

Q: Are there any specific foods or drinks that might interact with Iverhart Plus?

The official labeling states that the chewable tablet can be given directly or mixed with a small amount of food to encourage consumption. The label does not list any specific foods or beverages that are known to cause clinically significant interactions.

Q: What does official information clarify if Iverhart Plus causes drowsiness?

The term 'drowsiness' is not explicitly used, but official adverse reaction reports include depression/lethargy. Lethargy is defined as a state of reduced energy, activity, and alertness, and is listed among the documented nervous system-related effects.

Q: Can Iverhart Plus be used in patients with pre-existing heart conditions?

Regulatory documents state the product is to be used with caution in sick, debilitated, or underweight animals. Furthermore, all patients must be tested and confirmed heartworm-negative before initiating prevention. The label does not address specific pre-existing heart conditions.

Q: Is there a patient information leaflet (PIL) available for Iverhart Plus?

Yes, official labeling practices require that the full product safety and administration information is available. This information is provided through a product insert included with the packaging, and the full regulatory label is publicly available on government databases.

Q: Do studies examine the long-term effects of taking Iverhart Plus?

Studies related to extended use were conducted on young animals over a six-month period using elevated doses. These studies observed effects such as a decrease in testicular maturation in male puppies, providing some data on sustained, elevated exposure.

Q: Is the use of Iverhart Plus seasonal or year-round?

The official recommendation is to administer the medication monthly during the entire period when mosquitoes are active. Depending on the geographical area, this period may be only seasonal, or it may require year-round administration.

Q: Do official patient guides mention anything about stopping Iverhart Plus suddenly?

Official guidance emphasizes maintaining the monthly schedule to ensure consistent protection. The regulatory label states that if the interval between doses exceeds a month (30 days), the efficacy of the heartworm prevention can be reduced, making a late dose administration crucial.

Q: Are patients required to have specific monitoring while taking Iverhart Plus?

The official label mandates that all patients must be tested for existing heartworm infection before beginning the preventive program. No further specific ongoing routine laboratory monitoring is detailed in the standard patient administration instructions.

How should Iverhart Plus be stored and disposed of?

Storage and Handling Requirements

Official labeling mandates specific conditions for storing Iverhart Plus (ivermectin/pyrantel) to maintain product stability and ensure safety.

Condition	Regulatory Requirement
Temperature	Store at Controlled Room Temperature: 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C (86 F).
Protection	The product must be protected from light.
Container Rule	To maintain light protection, remove only one chewable at a time and return the blister card with the remaining chewables to its box.
Child Safety	Keep this and all drugs out of the reach of children.

Disposal Instructions

Disposal of unused or expired product and its container must be in accordance with all applicable local and national regulations. Due to the product's classification as very toxic to aquatic life, release to the environment must be avoided, and the material must be prevented from entering drains or watercourses.

Iverhart Plus